Autophagy, a fundamental cellular process responsible for degrading and recycling dysfunctional components, is crucial for maintaining cellular homeostasis by removing damaged organelles, protein aggregates, and intracellular pathogens [1-3]. It is essential in various physiological processes, such as development, immunity, and aging. The autophagic process involves the formation of double-membraned vesicles called autophagosomes, which envelope cellular components identified for degradation. These autophagosomes then fuse with lysosomes, where their contents are degraded and recycled, providing the cell with essential nutrients and energy.
Numerous studies have elucidated the intricate role of autophagy in disease progression [2,4-5]. For instance, autophagy can promote tumor cell survival or induce cell death in cancer. In neurodegenerative diseases like Alzheimer's and Parkinson's, impaired autophagy leads to the accumulation of toxic protein aggregates, contributing to neuronal dysfunction and cell death. Additionally, autophagy plays a crucial role in host defense against intracellular pathogens, highlighting its significance in infectious diseases. No wonder that in recent years, there has been a rise of interest in targeting autophagy as a therapeutic strategy for treating a wide range of diseases (Fig. 1), in particular, already mentioned cancer, infectious diseases, metabolic and neurodegenerative disorders, vascular diseases, and proteopathies [4,5]. Dysregulation of autophagy has been implicated in the pathogenesis of these diseases, making it an attractive target for drug discovery.
![Autophagy-targeting strategies are established in various human diseases. Adopted from [5]](img/blog/Autophagy/autophagy_1.png "Autophagy-targeting strategies are established in various human diseases. Adopted from [5]")
Fig. 1. Autophagy-targeting strategies are established in various human diseases.
Adopted from [5]
Recent advancements in autophagy drug discovery are paving the way for novel therapeutic approaches. Small molecule modulators and natural compounds with autophagy-inducing properties are gaining attention to become potential candidates for drug development [4-6]. In particular, small molecules are potent tools for regulating autophagy at various stages of the process (Fig. 2). Compounds, such as rapamycin and its derivatives, known as mTOR inhibitors, stimulate autophagy by inhibiting the mTOR pathway, thereby promoting autophagosome formation. Conversely, compounds like chloroquine and hydroxychloroquine block autophagy flux by inhibiting lysosomal acidification, leading to the accumulation of autophagosomes and impaired degradation of cargo. These small molecule modulators demonstrate versatile ways of manipulating autophagy in therapeutic settings.
![Various hierarchical sites of the autophagic signaling network are potential targets for drug discovery. Adopted from [1]](img/blog/Autophagy/autophagy_2.png "Various hierarchical sites of the autophagic signaling network are potential targets for drug discovery. Adopted from [1]")
Fig. 2. Various hierarchical sites of the autophagic signaling network are potential targets for drug discovery. Adopted from [1]
Moreover, preclinical and clinical studies [4,5] have shown promising results of autophagy-targeting drugs in various disease models, giving good hopes for effective treatments. Several drug candidates targeting autophagy are currently in development; for example, spermidine, a natural compound found in foods like soybeans and wheat germ, has demonstrated autophagy-inducing effects and potential benefits in neurodegenerative diseases. Additionally, novel small molecule inhibitors of autophagy regulators, such as ATG4B and ULK1, are being evaluated for their efficacy in cancer therapy. These case studies underscore the diverse strategies and therapeutic applications of autophagy-targeting drugs.
Despite the remarkable progress in autophagy drug discovery, several challenges remain. One major hurdle is achieving specificity in targeting autophagy pathways without disrupting essential cellular processes. In addition, optimizing drug efficacy and overcoming resistance mechanisms pose significant challenges in clinical translation. However, advancements in drug design, high-throughput screening, and personalized treatment offer more opportunities to overcome these challenges and develop more effective autophagy-targeting therapies. By explaining the mechanisms of action of potential drug candidates it will become possible not only to address critical challenges in drug development but also to pave the way for eventual application of autophagy-targeting therapeutics in clinical practice and provide novel treatment options for a wide range of diseases.
In conclusion, autophagy stands as one of the vanguard trends in drug discovery to combat formidable diseases and defeat stubborn medical problems. The key to unlock the full range of capabilities of autophagy-targeting therapies is yet to be found by continued exploration and innovation in this field.
Witnessing a growing interest in targeting autophagy, the Life Chemical team has released its new dedicated collection, an Autophagy Screening Compound Library (Fig. 3-4), to become an impressively deep source for your perfect selections.
Please, contact us at marketing@lifechemicals.com for any additional information and price quotations.
Download SD files with compound structures directly from our Downloads section
The compound selection can be customized based on your requirements, cherry picking is available.
Figure 3. Examples of screening compounds from the Life Chemicals Autophagy Screening Compound Library.
Figure 4. Target distribution in the Life Chemicals Autophagy Screening Compound Library.
References
1. Jiang, M., Wu, W., Xiong, Z., Yu, X., Ye, Z., & Wu, Z. (2024). Targeting autophagy drug discovery: Targets, indications, and development trends. European Journal of Medicinal Chemistry, 267, 116117. DOI: 10.1016/j.ejmech.2023.116117
2. Rubinsztein, D., Codogno, P. & Levine, B. (2012). Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 11, 709–730. DOI: 10.1038/nrd3802
3. Gao, L., Jauregui, C. E., & Teng, Y. (2017). Targeting autophagy as a strategy for drug discovery and therapeutic modulation. Future Medicinal Chemistry, 9(3), 335-345. DOI: 10.4155/fmc-2016-0210
4. Kocak, M., Ezazi Erdi, S., Jorba, G., Maestro, I., Farrés, J., Kirkin, V., et al. (2022). Targeting autophagy in disease: established and new strategies. Autophagy, 18(3), 473-495. DOI: 10.1080/15548627.2021.1936359
5. Kim, D., Hwang, H. Y., & Kwon, H. J. (2020). Targeting autophagy in disease: recent advances in drug discovery. Expert Opinion on Drug Discovery, 15(9), 1045-1063. DOI: 10.1080/17460441.2020.1773429
6. Xiang, H., Zhou, M., Li, Y., Zhou, L., & Wang, R. (2023). Drug discovery can be achieved by targeting the protein-protein interactions involved in autophagy. Acta Pharmaceutica Sinica B. 13(11), 4373-4390. DOI: 10.1016/j.apsb.2023.07.016
Comments ()